MartinRFarlowMD
Neurology • Indianapolis, INProfessor and Vice Chairman of Research, Department of Neurology; Core Leader, IADC Clinical Core
Dr. Farlow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
355 W. 16th Street, Suite 4700
IU Health Physicians-Dept Neurology
Indianapolis, IN 46202Phone+1 317-948-5450- Is this information wrong?
Education & Training
Indiana University School of MedicineResidency, Neurology, 1980 - 1983- Indiana University School of MedicineInternship, Internal Medicine, 1979 - 1980
- Indiana University School of MedicineClass of 1979
Certifications & Licensure
IN State Medical License 1979 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Indianapolis Monthly Castle Connolly, 2007, 2009, 2011, 2013
Clinical Trials
- Comparative Research of Alzheimer's Disease Drugs Start of enrollment: 2011 Apr 01
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSpatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease.Meichen Yu, Shannon L Risacher, Kwangsik T Nho, Qiuting Wen, Adrian L Oblak, Frederick W Unverzagt, Liana G Apostolova, Martin R Farlow, Jared R Brosch, David G Clark,...> ;Cell Reports. 2024 Feb 27
- 4 citationsEtiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.Nadkarni, N., Nadkarni, N., Shirzadi, Z., Schultz, S., Yau, W., Joseph-Mathurin, N., Fitzpatrick, C., Levin, R., Kantarci, K., Preboske, G., Jack, C., Farlow, M., Hass...> ;JAMA Neurology. 2023 Dec 1
- Edge time series components of functional connectivity and cognitive function in Alzheimer's disease.Evgeny J Chumin, Sarah A Cutts, Shannon L Risacher, Liana G Apostolova, Martin R Farlow, Brenna C McDonald, Yu-Chien Wu, Richard Betzel, Andrew J Saykin, Olaf Sporns> ;Brain Imaging and Behavior. 2024 Feb 1
- Join now to see all
Journal Articles
- A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and TreatmentJared R. Brosch, Martin R. Farlow, Neurology and Therapy
- The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s DiseaseGeorge T Grossberg, Peter J Snyder, Martin R Farlow, Brain
Lectures
- The Treatment of Alzheimer’s Disease: Comparing Guidelines162nd Annual Meeting, San Francisco, California, USA
- Severe Alzheimer Disease Responds Well to the 13.6 mg/24 hour Versus the 4.6 mg/24 hour Rivastigmine Patch166th Annual Meeting, San Francisco, California, USA
- The Treatment of Alzheimer’s Disease: Comparing GuidelinesAmerican Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA
- Join now to see all
Other
- Clinical features and diagnosis of dementia with Lewy bodiesFarlow MR, Hake AM
http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06 - Epidemiology, pathology, and pathogenesis of dementia with Lewy bodiesFarlow MR, Hake AM
http://www.uptodate.com/contents/epidemiology-pathology-and-pathogenesis-of-dementia-with-lewy-bodie
UpToDate, Wolters Kluwer Health - 2012-11-29 - Prognosis and treatment of dementia with Lewy bodiesFarlow MR, Hake AM
http://www.uptodate.com/contents/prognosis-and-treatment-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06
Press Mentions
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s DiseaseOctober 4th, 2022- Annovis Bio Inc. (ANVS) Stock Plunged During Current Market. Here’s the UpdateJuly 29th, 2021
- NervGen Pharma : Expands Alzheimer's Disease Scientific Advisory BoardJuly 12th, 2021
- Join now to see all
Grant Support
- Core--ClinicalNational Institute On Aging2006–2010
- Study Of AIT 082 In Mild Alzheimer'S Disease PatientsNational Center For Research Resources2000–2002
- Core-- ClinicalNational Institute On Aging1994–2002
- Ndd094 In 3 Cohorts For Mild To Moderate Alzheimers DiseaseNational Center For Research Resources1999
- Phase I Study Of AIT 082 In Healthly Elderly VolunteersNational Center For Research Resources1998–1999
Hospital Affiliations
Indiana University Health West HospitalAvon, Indiana- Northwest Health - La PorteLa Porte, Indiana
Indiana University Health University HospitalIndianapolis, Indiana
Eskenazi HealthIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
